Kimberly Umhoefer, DO
Internal Medicine · Battle Creek, MINPI 1225140007
Payments from drug & device makers
Across 515 payments — averaging $13.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$984
- Pfizer$830
- AstraZeneca$667
- Lilly USA, LLC$593
- Astellas Pharma US Inc$353
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,62499%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 109 | $1,097 |
| AbbVie(2 entities) | 86 | $984 |
| Pfizer | 70 | $830 |
| AstraZeneca | 27 | $667 |
| Lilly USA, LLC | 52 | $593 |
| Astellas Pharma US Inc | 20 | $353 |
| Boehringer Ingelheim | 23 | $352 |
| Johnson & Johnson | 26 | $298 |
| GSK | 15 | $217 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $156 |
| Dexcom, Inc. | 9 | $142 |
| Abbott | 6 | $113 |
| Amgen(2 entities) | 8 | $107 |
| Sanofi-aventis U.S. LLC | 7 | $102 |
| Biohaven Pharmaceuticals, Inc. | 5 | $81 |
| Merck | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 3 | $64 |
| Grifols USA, LLC | 4 | $57 |
| Esperion Therapeutics, Inc. | 4 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Novartis | 3 | $39 |
| Bayer | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $28 |
| Edwards Lifesciences | 1 | $19 |
| Exact Sciences | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,724 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $162,052 |
| JardianceEmpagliflozin | 108 | $129,115 |
| MounjaroTirzepatide | 69 | $81,867 |
| FarxigaDapagliflozin Propanediol | 49 | $59,047 |
| XareltoRivaroxaban | 47 | $47,054 |
| EliquisApixaban | 52 | $44,094 |
| TrulicityDulaglutide | 22 | $32,480 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $29,948 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $23,428 |
| JanuviaSitagliptin Phosphate | 19 | $15,864 |
| MyrbetriqMirabegron | 14 | $13,112 |
| LinzessLinaclotide | 11 | $8,652 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $8,380 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,336 |
| Rosuvastatin Calcium | 513 | $5,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,097 | $162,052101 claims |
| Boehringer IngelheimJardiance | $352 | $129,115108 claims |
| Lilly USA, LLCMounjaro, Trulicity | $593 | $114,34791 claims |
| AstraZenecaFarxiga | $667 | $59,04749 claims |
| Johnson & JohnsonXarelto | $298 | $47,05447 claims |
| PfizerEliquis | $830 | $44,09452 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $217 | $38,28438 claims |
| MerckJanuvia | $80 | $15,86419 claims |
| Astellas Pharma US IncMyrbetriq | $353 | $13,11214 claims |
| AbbVieLinzess, Synthroid | $984 | $10,96671 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Battle Creek
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.